



**Express Scripts Holding Company
Pharmacy and Therapeutics Committee
Proceedings
May 14, 2020**

New Drug Evaluations

The Committee reviewed the following new drugs.

- A. Durysta™ (bimatoprost ophthalmic implant for intracameral administration)** Allergan
- B. Jelmyto™ (mitomycin solution for pyelocalyceal administration)** UroGen Pharma
- C. Koselugo™ (selumetinib capsules)** AstraZeneca Pharmaceuticals
- D. Isturisa® (osilodrostat tablets)** Recordati Rare Diseases, Inc.
- E. Pemazyre™ (pemigatinib tablets)** Incyte Corporation
- F. Trodelvy™ (sacituzumab govitecan-hziy injection for intravenous use)** Immunomedics, Inc.
- G. Tukysa™ (tucatinib tablets)** Seattle Genetics
- H. Zeposia® (ozanimod capsules)** Celgene

New Clinical Line Extensions

The Committee reviewed the following new clinical line extensions.

- A. Bafiertam™ (monomethyl fumarate delayed-release capsules)** Banner Life Sciences
- B. Bynfezia Pen™ (octreotide acetate injection for subcutaneous use)** Sun Pharmaceutical
- C. Romidepsin injection for intravenous use** (Teva)

New Indications for Existing Products

The Committee reviewed the following new indications for existing products: See product inserts for specific wording.

- A. Braftovi® (encorafenib capsules)** Pfizer – New indication for use in combination with Erbitux® (cetuximab injection for intravenous use) for the treatment of metastatic colorectal cancer in adults with a BRAF V600E mutation, as detected by an Food and Drug Administration (FDA)-approved test, after prior therapy.
- B. Cymbalta® (duloxetine delayed-release capsules)** Lilly – Expanded age indication for fibromyalgia in pediatric patients 13 years to 17 years of age. Cymbalta is now indicated for fibromyalgia in adults and pediatric patients ≥ 13 years of age.
- C. Epclusa® (sofosbuvir/velpatasvir tablets)** Gilead – Expanded age indication for use in patients ≥ 6 years of age or weighing ≥ 17 kg with chronic hepatitis C virus genotype 1, 2, 3, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis or with decompensated cirrhosis for use in combination with ribavirin.
- D. Eucrisa® (crisaborole ointment, 2%)** Pfizer – Expanded age indication to include pediatric patients 3 months to less than 24 months of age. Eucrisa is now indicated for topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients ≥ 3 months of age.
- E. Imfinzi® (durvalumab injection for intravenous use)** AstraZeneca – New indication for use in combination with etoposide and either carboplatin or cisplatin, for the first-line treatment of extensive-stage small cell lung cancer in adults.
- F. Jublia® (efinaconazole topical solution)** Bausch Health – Expanded age indication to include patients 6 years to 17 years of age. Jublia is indicated for topical treatment of onychomycosis of the toenail(s) due to *Trichophyton rubrum* and *Trichophyton mentagrophytes*.

- G. Ofev® (nintedanib capsule)** Boehringer Ingelheim – New indication for the treatment of chronic fibrosing interstitial lung diseases with a progressive phenotype.
- H. Opdivo® (nivolumab injection for intravenous use) + Yervoy® (ipilimumab injection for intravenous use)** Bristol-Myers Squibb – Expanded indication for the use of Opdivo and Yervoy in combination for the treatment of patients with hepatocellular carcinoma who have been previously treated with Nexavar® (sorafenib tablets).
- I. Reblozyl® (luspatercept-aamt injection for subcutaneous use)** Bristol-Myers Squibb – New indication for the treatment of anemia failing an erythropoiesis stimulating agent and requiring two or more red blood cell units over 8 weeks in adult patients with very low- to intermediate-risk myelodysplastic syndromes with ring sideroblasts or with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis.
- J. Taltz® (ixekizumab injection for subcutaneous use)** Lilly – Expanded age indication to include pediatric patients 6 years to less than 18 years of age with plaque psoriasis. Taltz is now indicated for the treatment of moderate-to-severe plaque psoriasis in patients ≥ 6 years of age who are candidates for systemic therapy or phototherapy.
- K. Zejula® (niraparib capsules)** GlaxoSmithKline – New indication for the first-line maintenance treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer in adults who are in a complete or partial response to first-line platinum-based chemotherapy.

All trademarks are the property of their respective owners.